ROTH Capital downgrades Catalyst Pharmaceuticals Inc. (CPRX) rating to a Neutral


Catalyst Pharmaceuticals Inc.’s recent filing unveils that its President and CEO MCENANY PATRICK J unloaded Company’s shares for reported $0.35 million on May 15. In the deal valued at $13.23 per share,26,151 shares were sold. As a result of this transaction, MCENANY PATRICK J now holds 3,945,436 shares worth roughly $ 51.05 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Tierney David S sold 30,000 shares, generating $504,900 in total proceeds. Upon selling the shares at $16.83, the Director now owns 313,541 shares.

Before that, GRANDE ALICIA sold 50,000 shares. Catalyst Pharmaceuticals Inc. shares valued at $835,100 were divested by the VP, Treasurer and CFO at a price of $16.70 per share. As a result of the transaction, GRANDE ALICIA now holds 50,557 shares, worth roughly $0.65 million.

ROTH Capital downgraded its Catalyst Pharmaceuticals Inc. [CPRX] rating to a Neutral from a a Buy in a research note published on Tuesday, August 24, 2022; the price target was increased to $15.50 from $10. PT values the company’s stock at a premium of 16.52 to its Tuesday closing price.

Price Performance Review of CPRX

On Tuesday, Catalyst Pharmaceuticals Inc. [NASDAQ:CPRX] saw its stock fall -7.04% to $12.94. On the same session, the stock had its day’s lowest price of $12.905, but rose to a high of $13.92. Over the last five days, the stock has lost -8.94%. Catalyst Pharmaceuticals Inc. shares have fallen nearly -30.43% since the year began. Nevertheless, the stocks have fallen -7.44% over the past one year. While a 52-week high of $22.11 was reached on 01/13/23, a 52-week low of $11.09 was recorded on 06/01/23. SMA at 50 days reached $13.70, while 200 days put it at $15.33. A total of 1.67 million shares were traded, compared to the trading of 0.91 million shares in the previous session.

Levels Of Support And Resistance For CPRX Stock

The 24-hour chart illustrates a support level at 12.59, which if violated will result in even more drops to 12.24. On the upside, there is a resistance level at 13.60. A further resistance level may holdings at 14.27. The Relative Strength Index (RSI) on the 14-day chart is 35.93, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.53, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.50%. Stochastics %K at 10.39% indicates the stock is a buying.

How much short interest is there in Catalyst Pharmaceuticals Inc.?

A steep rise in short interest was recorded in Catalyst Pharmaceuticals Inc. stocks on Aug 14, 2023, dropping by -0.44 million shares to a total of 6.75 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 7.19 million shares. There was a decline of -6.52%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 8.02% of the overall stock float, the days-to-cover ratio (short ratio) fell to 4.97.

According to FactSet, Catalyst Pharmaceuticals Inc.’s share price will average $23.10 in the next year, based on opinions of analysts polled by the firm. This is up nearly 72.41 percent from its previous closing price of $13.92. Analysts expect Catalyst Pharmaceuticals Inc. stock to reach the higher price of $27.00, while the lowest price estimate is $15.50. However, 5 analysts have rated CPRX stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here